A Phase 1/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 Monotherapy, or in Combination With Pomalidomide, With and Without Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ParadigMM-1B)

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pavurutamab (Primary) ; Dexamethasone; Dexamethasone; Pomalidomide
Indications Multiple myeloma
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms ParadigMM-1B
Sponsors Amgen

Most Recent Events

13 Sep 2023 Status changed from completed to discontinued due to business decision, not safety reasons.
11 Jul 2023 Status changed from active, no longer recruiting to completed.
25 May 2023 This trial has been discontinued in Germany, according to European Clinical Trials database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight